

Taxiarchis Kourelis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1712376/publications.pdf>

Version: 2024-02-01

315
papers

5,094
citations

109137

35
h-index

143772

57
g-index

321
all docs

321
docs citations

321
times ranked

5181
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	2.5	7
2	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	2.1	9
3	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
4	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
5	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
6	Characteristics and risk factors for thrombosis in <sc>POEMS</sc> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
7	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
8	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
9	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
10	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
11	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. Mayo Clinic Proceedings, 2022, 97, 294-307.	1.4	16
12	Proteomic profiling of sporadic lateâ€“onset nemaline myopathy. Annals of Clinical and Translational Neurology, 2022, 9, 391-402.	1.7	4
13	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . Leukemia, 2022, 36, 1429-1431.	3.3	8
14	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	2.5	11
15	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	2.5	13
16	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, S195-S196.	0.6	0
17	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	1.3	6
18	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0

#	ARTICLE	IF	CITATIONS
19	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59.	2.8	3
20	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
21	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427.	0.6	2
22	Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. <i>British Journal of Haematology</i> , 2022, 199, 95-99.	1.2	14
23	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. <i>Blood Advances</i> , 2022, 6, 5429-5435.	2.5	3
24	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
25	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
26	Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
27	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
28	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436.	1.1	3
29	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
30	Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
31	Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. <i>ESC Heart Failure</i> , 2021, 8, 750-755.	1.4	7
32	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
33	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935.	1.3	5
34	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
35	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
36	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036.	2.5	9
38	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
39	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021, 11, 45.	2.8	24
40	Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021, 149, 741-742.	2.3	2
41	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
42	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
43	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 1797-1804.	2.5	26
44	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021, 5, 2101-2105.	2.5	7
45	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
46	The Clinical Impact of Proteomics in Amyloid Typing. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1122-1127.	1.4	9
47	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
48	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
49	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
50	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	2.5	13
51	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
52	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
53	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , 2021, 97, 67-73.	0.8	4
54	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	2.8	9

#	ARTICLE	IF	CITATIONS
55	Poster: MM-429: Impact of Prolonged Lenalidomide Maintenance (â‰¥3 years) and Outcomes in Patients with Multiple Myeloma Post-Autologous Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S252.	0.2	0
56	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
57	Clinical Heterogeneity of the VEXAS Syndrome. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2653-2659.	1.4	58
58	Amyloid light-chain deposition in a schwannoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 26, 101301.	0.2	0
59	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
60	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
61	Ageing-associated immune system changes in multiple myeloma: The dark side of the moon.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100494.	0.7	6
62	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	0.6	3
63	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0
64	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ²-NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
65	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
66	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio â‰¥100. <i>Blood</i> , 2021, 138, 1617-1617.	0.6	0
67	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.	0.6	1
68	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.	0.6	0
69	Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , 2021, 138, 401-401.	0.6	1
70	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
71	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2
72	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021, 138, 3773-3773.	0.6	0
74	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , 2021, 138, 2711-2711.	0.6	2
75	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021, 138, 4656-4656.	0.6	0
76	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.	0.6	0
77	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 1632-1632.	0.6	0
78	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021, 138, 2691-2691.	0.6	0
79	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3774-3774.	0.6	1
80	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1619-1619.	0.6	0
81	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543.	0.6	0
82	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021, 138, 1630-1630.	0.6	0
83	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	0.6	4
84	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021, 138, 119-119.	0.6	0
85	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650.	0.6	0
86	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021, 138, 3838-3838.	0.6	1
87	Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications. <i>Frontiers in Oncology</i> , 2021, 11, 801851.	1.3	13
88	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma” the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
89	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
90	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	2.0	10

#	ARTICLE	IF	CITATIONS
91	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14
92	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
93	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
94	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	2.0	4
95	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
96	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
97	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	3.3	15
98	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	3.3	29
99	Colon perforation in multiple myeloma patients â€ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	1.3	3
100	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	3.2	32
101	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
102	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2
103	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	2.0	17
104	A Proteomic Atlas of CardiacÂAmyloid Plaques. JACC: CardioOncology, 2020, 2, 632-643.	1.7	20
105	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	2.5	58
106	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	2.8	59
107	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	2.8	12
108	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8

#	ARTICLE	IF	CITATIONS
109	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4
110	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	2.8	8
111	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
112	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954.	1.4	7
113	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2020, 10, 33.	2.8	26
114	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
115	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. <i>Leukemia</i> , 2020, 34, 2749-2753.	3.3	43
116	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
117	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. <i>British Journal of Haematology</i> , 2020, 190, 79-83.	1.2	3
118	The Impact of Proliferating Polyclonal Plasma Cells on Outcome after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S239.	2.0	0
119	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
120	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
121	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , 2020, 95, E222-E225.	2.0	15
122	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
123	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326.	2.5	8
124	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.	0.6	4
125	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
126	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4

#	ARTICLE	IF	CITATIONS
127	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
128	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
129	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
130	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
131	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	2.5	20
132	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2020, 136, 28-29.	0.6	2
133	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
134	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
135	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
136	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
137	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
138	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
139	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
140	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	0.6	0
141	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
142	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
143	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
144	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , 2020, 136, 15-15.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
146	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
147	A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	0.6	2
148	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center ScRNA-Seq Study. <i>Blood</i> , 2020, 136, 6-8.	0.6	0
149	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18
150	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. <i>Leukemia</i> , 2019, 33, 254-257.	3.3	53
151	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
152	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
153	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
154	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
155	Autologous Stem Cell Transplantation in Patients with AL Amyloidosis with Impaired Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S389-S390.	2.0	0
156	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
157	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229.	2.5	7
158	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
159	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
160	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
161	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. <i>Blood Cancer Journal</i> , 2019, 9, 72.	2.8	34
162	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22

#	ARTICLE	IF	CITATIONS
163	Autologous Stem Cell Transplant for IgM Related AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S388-S389.	2.0	0
164	Sporadic late-onset nemaline myopathy. <i>Neurology</i> , 2019, 93, e298-e305.	1.5	45
165	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
166	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
167	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
168	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	1.2	17
169	Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CAMEL). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S30.	2.0	2
170	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
171	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
172	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
173	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
174	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
175	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
176	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
177	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
178	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 744-750.	2.5	28
179	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e301-e302.	0.2	0
180	Venetoclax For The Treatment of Translocation AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e332.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
182	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
183	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
184	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
185	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
186	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
187	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , 2019, 134, 3510-3510.	0.6	1
188	A Proteomic Atlas of Cardiac Amyloidosis. <i>Blood</i> , 2019, 134, 1790-1790.	0.6	1
189	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
190	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
191	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
192	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	0.6	2
193	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
194	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	0.6	13
195	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
196	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16
197	PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. <i>HemaSphere</i> , 2019, 3, 641.	1.2	0
198	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	0.6	0
200	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	0.6	0
201	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	0.6	0
202	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	0.6	0
203	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	0.6	0
204	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. Blood, 2019, 134, 1770-1770.	0.6	0
205	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	0.6	0
206	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	0.6	1
207	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	0.6	1
208	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	0.6	0
209	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. Blood, 2019, 134, 2013-2013.	0.6	0
210	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	0.6	1
211	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
212	Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset NemaLine Myopathy with Associated Monoclonal Gammopathy of Unknown Significance. Biology of Blood and Marrow Transplantation, 2018, 24, S124-S125.	2.0	1
213	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	3.3	64
214	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	1.7	10
215	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	2.0	14
216	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21

#	ARTICLE	IF	CITATIONS
217	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
218	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
219	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
220	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
221	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
222	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
223	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018, 32, 719-728.	3.3	13
224	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
225	POEMS Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 119-139.	0.9	28
226	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100
227	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
228	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
229	Utility and prognostic value of ¹⁸ F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.	2.0	19
230	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.	2.5	23
231	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.	2.5	23
232	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
233	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159.	2.0	8
234	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3

#	ARTICLE	IF	CITATIONS
235	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
236	MASS‑FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. American Journal of Hematology, 2018, 93, E368-E370.	2.0	34
237	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	2.2	46
238	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
239	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood, 2018, 132, 670-672.	0.6	42
240	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. Blood, 2018, 132, 1879-1879.	0.6	1
241	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
242	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
243	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
244	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
245	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
246	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	0.6	0
247	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
248	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
249	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
250	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
251	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
252	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018, 132, 4502-4502.	0.6	0
254	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 1902-1902.	0.6	1
255	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018, 132, 5594-5594.	0.6	0
256	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.	0.6	0
257	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018, 132, 5610-5610.	0.6	0
258	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
259	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.	0.6	0
260	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
261	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
262	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
263	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.	0.6	1
264	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
265	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
266	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
267	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
268	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
269	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
270	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , 2017, 129, 299-306.	0.6	99

#	ARTICLE	IF	CITATIONS
271	Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.	0.6	21
272	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
273	A Widely Applicable Method for Resolving Therapeutic Monoclonal Drug Interference for Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e45.	0.2	0
274	Going off the Gold-Standard: Replacing Electrophoretic Methods With Mass Spectrometry for Plasma Cell Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e18-e19.	0.2	1
275	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
276	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
277	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.3	0
278	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
279	Induction therapy pre autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
280	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
281	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
282	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
283	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5
284	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
285	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
286	Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study. <i>Blood</i> , 2016, 128, 5476-5476.	0.6	0
287	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
288	Temozolomide induced bone marrow Suppression: A single institution outcome analysis and review of the literature. <i>American Journal of Hematology</i> , 2015, 90, E183-4.	2.0	17

#	ARTICLE	IF	CITATIONS
289	Improving strategies for the diagnosis of cardiac amyloidosis. Expert Review of Cardiovascular Therapy, 2015, 13, 945-961.	0.6	6
290	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	1.4	16
291	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	0.6	3
292	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	0.6	5
293	Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. Blood, 2015, 126, 5192-5192.	0.6	0
294	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	2.0	4
295	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	2.0	32
296	Temozolomide Induced Bone Marrow Suppression- a Single Institution Outcome Analysis and Review of Literature. Blood, 2014, 124, 1602-1602.	0.6	3
297	Immunoglobulin Variable Region Family Usage and Outcomes of Patients with Systemic Light Chain Amyloidosis. Blood, 2014, 124, 3402-3402.	0.6	1
298	Myeloid malignancy presenting with a platelet storage pool disorder. Leukemia and Lymphoma, 2013, 54, 1800-1801.	0.6	3
299	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 690-693.	2.0	30
300	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	2.0	34
301	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
302	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	0.6	0
303	Mastocytosis causing refractory hypotension after coronary angiography. International Journal of Cardiology, 2012, 156, e43-e44.	0.8	1
304	Trisomy 8 as the sole cytogenetic abnormality in an adult patient with acute lymphoblastic leukemia. Cancer Genetics, 2012, 205, 337-338.	0.2	1
305	Metformin and cancer: new applications for an old drug. Medical Oncology, 2012, 29, 1314-1327.	1.2	254
306	Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab. Acta Haematologica, 2011, 126, 40-43.	0.7	9

#	ARTICLE	IF	CITATIONS
307	Amitriptyline and Prochlorperazine Inhibit Proinflammatory Mediator Release From Human Mast Cells. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 385-387.	0.7	20
308	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. <i>European Journal of Dermatology</i> , 2010, 20, 865-7.	0.3	34
309	Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF- κ B activation. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 397-405.	1.1	32
310	Human Mast Cells Stimulate Activated T Cells. <i>Annals of the New York Academy of Sciences</i> , 2008, 1144, 74-82.	1.8	42
311	Tc2 Response at the Onset of COPD Exacerbations. <i>Chest</i> , 2008, 134, 483-488.	0.4	39
312	Defective Peripheral Blood Endothelial Cell Progenitors in Patients with Scleroderma and Psoriatic Arthritis. <i>Blood</i> , 2008, 112, 4724-4724.	0.6	0
313	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1383-1387.	0.8	33
314	Activated peripheral blood and endothelial cells in thalassemia patients. <i>Annals of Hematology</i> , 2001, 80, 577-583.	0.8	71
315	Reduced CD43 Expression on the Neutrophils of MDS Patients Correlates With an Activated Phenotype of These Cells. <i>International Journal of Hematology</i> , 2001, 73, 483-491.	0.7	16